



Iowa Department of Human Services

Terry E. Branstad
Governor

Kim Reynolds
Lt. Governor

Charles M. Palmer
Director

Iowa Medicaid Drug Utilization Review (DUR) Commission Meeting

August 5, 2015

**Location: Learning Resource Center
Fairmeadows Room
3550 Mills Civic Parkway
West Des Moines, Iowa 50265**

Time: 9:30 a.m. – 1:30 p.m.

Tentative Agenda

1. Welcome & Introductions
 - a) Commission Members and Staff
 - b) Approval of the Minutes
2. Commission Business
 - a) Annual Completion of Conflict of Interest Disclosure
 - b) Annual DUR Commission Chairperson and Vice Chairperson Elections
 - c) DHS Recommendation Letter – June 2015
 - d) Annual DUR CMS Report – FFY14
3. IME Updates
4. Prevalence Report Summary
5. Case Studies
6. Public Comment (See Conflict of Interest Disclosure Form)
7. Focus Studies/Provider Education Initiatives
 - a) Short-Acting Opioid Overutilization – Concurrent Therapy – Follow Up
 - b) Metoclopramide Utilization - Updated
 - c) Modafinil Utilization – Initial Review
 - d) Duplicate Antidepressants – Initial Review
8. Public Comment (See Conflict of Interest Disclosure Form)
9. Prior Authorization
 - a) Topical Antifungals for Onychomycosis – Initial Review - Updated
 - b) Alpha-1 Proteinase Inhibitors – Initial Review

- c) Lumacaftor/Ivacaftor (Orkambi™) – Initial Review
- d) Biologicals for Ankylosing Spondylitis – Initial Review
- e) Biologicals for Inflammatory Bowel Disease – Initial Review
- f) Biologicals for Plaque Psoriasis – Initial Review
- g) Topical Corticosteroids – Second Review
- h) Ivacaftor (Kalydeco®) – Second Review
- i) Idiopathic Pulmonary Fibrosis – Second Review
- j) Edoxaban (Savaysa®) – Second Review
- k) Select Oncology Agents – Second Review

10. Miscellaneous

- a) DUR Digest Vol. 28, No. 1 – Initial Review
- b) MedWatch

11. Executive Closed Session

- a) Approval of Minutes
- b) Member Profiles

12. Adjournment

Individuals attending meetings of the DUR Commission shall have an opportunity to address the Commission. This opportunity will be granted twice during the open portion of the meeting. In order to accommodate all interested parties, all speakers are requested to limit their comments to **5 minutes or less**. If you represent a drug manufacturer as an employee, as a contractor, as a member of the manufacturer's Speaker Bureau, or by any other means, we expect you to cover your individual product or entire product line in that five-minute time frame. Speakers who represent multiple manufacturers will share their 5 minutes with the other manufacturer representative(s) whose product they are speaking on.

www.iadur.org

For more information contact the DUR Project Coordinator, Pamela Smith, R.Ph., at info@iadur.org or (515) 974-3131

*****Next Meeting October 7, 2015***
Learning Resource Center
3550 Mills Civic Parkway, West Des Moines, IA 50265**